Document is current
Any future updates will be listed below
-
Authors
Hayashi, Hiroki
Sun, Jiao
Yanagida, Yuka
Otera, Takako
Sasai, Miwa
Chang, Chin Yang
Tai, Jiayu A.
Nishikawa, Tomoyuki
Yamashita, Kunihiko
Sakaguchi, Naoki
Yoshida, Shota
Baba, Satoshi
Shimamura, Munehisa
Okamoto, Sachiko
Amaishi, Yasunori
Chono, Hideto
Mineno, Junichi
Rakugi, Hiromi
Morishita, Ryuichi
Yamamoto, Masahiro
Nakagami, Hironori
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP20nk0101602, JP21nf0101623h102)
- License Information
-
More Information
Article History
Received: 2 September 2022
Accepted: 16 November 2022
First Online: 3 December 2022
Competing interests
: The Department of Health Development and Medicine is an endowed department supported by Anges, Daicel, and FunPep. The Department of Clinical Gene Therapy is financially supported by Novartis, AnGes, Shionogi, Boeringher, Fancl, Saisei Mirai Clinics, Rohto, and FunPep. R.M. is a stockholder of FunPep and AnGes. T.O. is the employee of AnGes. K.Y., N.S. are the employees of Daicel. S.O., Y.A., H.C., and J.M. are the employees of Takara Bio. The funders provided support in the form of salaries for the authors but did not have any additional role in the study design, data analysis, decision to publish, or preparation of the manuscript. All other authors declare no competing interests.
